Viridian Therapeutics, Inc.
VRDN$732M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaWALTHAM143 employees
Drugs in Pipeline
5
Phase 3 Programs
5
Upcoming Catalysts
4
Next Catalyst
Apr 1, 2026
4dMarket Overview
Stock performance and key metrics
VRDN News
Catalyst Timeline
4 upcoming, 2 past
Phase 3Next
VRDN-003 Phase 3 Results Expected
Apr 1, 2026EstimatedVRDN-003195
Primary completion for VRDN-003 trial (NCT06812325) in Thyroid Eye Disease (TED)
Source3 more catalysts beyond 14 days
Start a 48h free trial to see all upcoming catalysts
Drug Pipeline
VRDN-001 10 mg/kg
Thyroid Eye Disease
Intervention/Treatment
Thyroid Eye Disease
VRDN-001 Phase 3 Cohort (THRIVE)
Thyroid Eye Disease
Veligrotug (VRDN-001)
Thyroid Eye Disease
VRDN-003
Thyroid Eye Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
VRDN-001 10 mg/kg | Phase 3 | Thyroid Eye Disease | - | - |
Intervention/Treatment | Phase 3 | Thyroid Eye Disease | - | - |
VRDN-001 Phase 3 Cohort (THRIVE) | Phase 3 | Thyroid Eye Disease | - | - |
Veligrotug (VRDN-001) | Phase 3 | Thyroid Eye Disease | - | - |
VRDN-003 | Phase 3 | Thyroid Eye Disease | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply